These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Janson ET; Rönnblom L; Ahlström H; Grandér D; Alm G; Einhorn S; Oberg K Ann Oncol; 1992 Sep; 3(8):635-8. PubMed ID: 1450046 [TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Prümmer O Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744 [TBL] [Abstract][Full Text] [Related]
4. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163 [TBL] [Abstract][Full Text] [Related]
5. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959 [TBL] [Abstract][Full Text] [Related]
6. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative. Russo D; Candoni A; Grattoni R; Minisini R; Rosti G Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589 [TBL] [Abstract][Full Text] [Related]
8. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128 [TBL] [Abstract][Full Text] [Related]
9. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors. Oberg K; Alm GV J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277 [TBL] [Abstract][Full Text] [Related]
10. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2. Nolte KU; Günther G; von Wussow P Eur J Immunol; 1996 Sep; 26(9):2155-9. PubMed ID: 8814261 [TBL] [Abstract][Full Text] [Related]
11. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Milella M; Antonelli G; Santantonio T; Currenti M; Monno L; Mariano N; Angarano G; Dianzani F; Pastore G Liver; 1993 Jun; 13(3):146-50. PubMed ID: 8336526 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo. Davis-Daneshfar A; Böni R; von Wussow P; Joller H; Burg G; Dummer R J Immunother; 1997 May; 20(3):208-13. PubMed ID: 9181459 [TBL] [Abstract][Full Text] [Related]
13. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients. Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814 [TBL] [Abstract][Full Text] [Related]
14. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha. Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890 [TBL] [Abstract][Full Text] [Related]
15. Detection of anti-interferon-alpha 2a antibodies in chronic liver disease. Ikeda Y; Miyake K; Toda G; Yamada H; Yamanaka M; Oka H J Gastroenterol Hepatol; 1989; 4(5):411-8. PubMed ID: 2491207 [TBL] [Abstract][Full Text] [Related]
16. Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia. von Wussow P; Pralle H; Hochkeppel HK; Jakschies D; Sonnen S; Schmidt H; Müller-Rosenau D; Franke M; Haferlach T; Zwingers T Blood; 1991 Jul; 78(1):38-43. PubMed ID: 2070058 [TBL] [Abstract][Full Text] [Related]
17. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. Scagnolari C; Casato M; Bellomi F; De Pisa F; Turriziani O; Coviello R; Pirro MR; Dianzani F; Antonelli G Clin Diagn Lab Immunol; 2003 Jan; 10(1):70-7. PubMed ID: 12522042 [TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy). Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P; J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789 [TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3. Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083 [TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. Myhr KM; Ross C; Nyland HI; Bendtzen K; Vedeler CA Neurology; 2000 Nov; 55(10):1569-72. PubMed ID: 11094118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]